May 2026 Research Update

This month added evidence that diagnosing adult hypophosphatasia (HPP) may be more reliable when routine lab results are interpreted together with a few clinical clues, rather than relying on one test alone. In one study, a simple 4-part score helped distinguish adults with genetically confirmed HPP from people who had persistently low alkaline phosphatase (ALP) for other reasons. This matters because low ALP can happen in multiple situations, and the study focused on practical information that is often already available in routine care. [1]

In the study, adults with confirmed HPP tended to have lower ALP and higher PLP (a form of vitamin B6 that can build up when ALP is low) than the comparison group. The tool combined ALP with height, family history, and chronic muscle or bone pain, and it still performed reasonably well when tested in a separate group of patients. In plain language, the findings support a step of looking at the whole picture (lab values plus a few life-history details) when adult HPP is being considered. [1]

For patients, this research mainly matters at the diagnosis stage, especially for adults who have repeatedly low ALP and symptoms that could fit HPP. It does not prove that the tool is ready for universal use, but it does show that a small set of everyday clinical details can add helpful context to low ALP and PLP results. What remains uncertain is how well this approach works in broader, more diverse populations outside the groups studied, and how it performs across different healthcare settings. For now, it is best understood as a practical research step toward clearer adult diagnosis, rather than a change in care by itself. [1]

This month, animal studies explored how boosting alkaline phosphatase activity might help HPP, and also what could interfere with benefits or raise safety questions. One mouse study reported improved early growth, survival, and bone findings after a fetal cell-based gene approach designed to increase TNAP (the enzyme missing in HPP). Another mouse study suggested that chronic kidney disease (CKD) can blunt the skeletal benefits of asfotase alfa (an enzyme replacement therapy) and can coincide with more calcification in the kidneys and blood vessels in that model. [2] [3]

In the fetal cell-therapy experiment, treated HPP mice had higher TNAP activity and lower PPi (a natural substance that helps prevent calcification problems in the body) along with improved bone formation measures in early life. The transplanted cells were found mainly at the injection site rather than spreading into bone marrow, suggesting the benefit may have come from enzyme activity reaching the body through the bloodstream rather than from rebuilding bone tissue directly. This is still short-term, early-stage research, but it clarifies that raising TNAP activity before birth can change early outcomes in this severe mouse model. [2]

In the CKD study, asfotase alfa partly improved bone measurements in HPP mice, but those benefits were smaller when CKD was present. The combination of CKD and asfotase alfa was also linked to more ectopic calcification (calcification in places it should not occur), including kidney and vascular calcification, along with signs of kidney inflammation in the model. In plain language, the study raises a cautionary research signal that kidney disease and high-phosphate conditions may change the risk-benefit balance of enzyme replacement in ways that need careful study in people. [3]

For patients and caregivers, these results are mainly about what might matter in the future, not about immediate changes in treatment. The fetal cell-based gene approach was tested only in mice and only over a short early-life window, so it cannot predict whether it would be safe or effective in humans. The CKD mouse study highlights a specific open question that may be relevant for some families: other health conditions, especially kidney disease and mineral balance problems, could influence both benefits and unwanted calcification risks during enzyme-based treatment, but this has not been proven in people. Together, these studies help clarify which biological factors researchers are watching most closely (TNAP activity, PPi levels, bone mineralization, and calcification outside the skeleton) as they design future therapies and safety studies. [2] [3]

This month, case reports emphasized how widely HPP can vary, even within the same family and even when genetic testing identifies clear ALPL changes. In one infant case, symptoms began before birth and included growth problems, feeding and breathing difficulties, seizures responsive to vitamin B6, bone changes, and very low ALP, with progression reported when enzyme replacement was not used. In a small family series, one sibling could have clear X-ray changes with few symptoms, while another had more noticeable problems, showing that genes alone do not fully predict daily impact. [4] [5]

Across the family series, asfotase alfa was linked with improved bone imaging findings and normalization of vitamin B6 levels after treatment began, but skull bone fusion (craniosynostosis) still appeared in two treated children and required surgical evaluation or treatment. The reports also described situations where parents carried ALPL changes without symptoms, while children were more affected, including compound heterozygous inheritance (one variant from each parent). In plain language, these cases reinforce that HPP is not a single predictable path, and monitoring concerns may differ between people with similar genetics. [5]

For families, these reports mainly add understanding of what variability can look like, rather than providing general rules. They show that severe infant illness can include breathing and feeding problems and vitamin B6-responsive seizures, and that progression can occur without enzyme replacement in an infantile case, but a single case cannot predict what will happen for another child. They also show that improvements in bone images during asfotase alfa treatment can occur alongside skull-shape complications in some children, so outcomes can move in different directions at the same time. What remains uncertain is how to predict who will have mild versus more serious symptoms based on genetics alone, since the same variants did not map neatly to the same experiences within families. [4] [5]